(Q43181980)

15 November 2017

title

Bevacizumab: in previously treated glioblastoma (English)

1 reference

15 November 2017

1 reference

Marit D Moen

1

1 reference

15 November 2017

publication date

1 January 2010

1 reference

15 November 2017

1 reference

15 November 2017

volume

70

1 reference

15 November 2017

issue

2

1 reference

15 November 2017

page(s)

181-189

1 reference

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

15 November 2017

cites work

1 reference

12 December 2020

Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma

1 reference

12 December 2020

Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

1 reference

12 December 2020

Bevacizumab: in first-line treatment of metastatic breast cancer

1 reference

12 December 2020

A new target for tumor therapy

1 reference

12 December 2020

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

12 December 2020

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

12 December 2020

Clinical pharmacokinetics of bevacizumab in patients with solid tumors.

1 reference

12 December 2020

Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer

1 reference

12 December 2020

Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas.

1 reference

12 December 2020

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

1 reference

12 December 2020

Biological mechanisms of bevacizumab-associated adverse events

1 reference

12 December 2020

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

12 December 2020

Lessons learned in the development of targeted therapy for malignant gliomas.

1 reference

12 December 2020

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues

1 reference

12 December 2020

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

12 December 2020

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

12 December 2020

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

1 reference

12 December 2020

The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival

1 reference

12 December 2020

10.2165/11203890-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

15 November 2017

1052953675

0 references

1 reference